Preclinical research suggests that recently developed non-steroidal GR antagonists, such as CORT125134, which accomplished phase III clinical trial for Cushing’s syndrome, hold therapeutic potential for the treatment of diseases associated with GR overactivation [77]. Here, NR3C1 is linked to Cushing syndrome due to macronodular adrenal hyperplasia.